| Cost-effectiveness of community-acquired pneumonia therapy. | |
| | |
MedLine Citation:
|
PMID: 19807352 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Community-acquired pneumonia is a common disease in adults and substantially contributes to morbidity and mortality in the USA and worldwide. Due to the significant costs associated with this disease, there is increasing pressure to evaluate the variation in practices among healthcare providers. The processes of care related to the diagnosis, management and prevention of community-acquired pneumonia are reviewed. Furthermore, the cost-effective strategies for community-acquired pneumonia and the medical evidence that support their usage are outlined. |
| | |
Authors:
|
Raymond J Foley; Mark L Metersky |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of pharmacoeconomics & outcomes research Volume: 3 ISSN: 1744-8379 ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Publication Date: 2003 Dec |
Date Detail:
|
Created Date: 2009-10-07 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101132257 Medline TA: Expert Rev Pharmacoecon Outcomes Res Country: England |
Other Details:
|
Languages: eng Pagination: 749-56 Citation Subset: - |
Affiliation:
|
Pulmonary Division, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1225, USA. Metersky@nso.uchc.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cost-effectiveness of Advair(R): fluticasone propionate and salmeterol combination.
Next Document: Potential cost-effectiveness of colorectal cancer chemoprevention with nonsteroidal anti-inflammator...